The newest version of Cologuard, an at-home colon cancer screening test, results in fewer false positives that can lead to unnecessary follow-up procedures. Cologuard Plus also gives people more time ...

The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...

MADISON (WKOW) — Exact Sciences has launched its new "Cologuard Plus" test. This test is gaining attention as the most accurate non-invasive colorectal screening test currently available. The ...

SHREVEPORT, La. -- No one likes to get a colonoscopy, but it's an important tool in the fight against colon cancer. There is an easier way: Cologuard is a non-invasive, effective, and affordable ...

MADISON, Wis., Jan. 18, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced performance data for a second-generation Cologuard (multi-target stool DNA) test showing overall ...

Exact Sciences, specializing in advanced cancer diagnostics, is recognized for its cutting-edge tests facilitating early cancer detection. 2022 saw significant milestones, testing over 12 million ...

Exact Sciences EXAS recently received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus. This marks a significant advancement for the company in the field of colorectal ...

Exact Sciences completed 1.69 million Cologuard tests in 2019, and while the test was found to have 92 percent sensitivity and 87 percent specificity rates for detecting colorectal cancer, it remains ...

WASHINGTON (AP) — The Food and Drug Administration on Monday approved the first screening test for colon cancer that uses patients’ DNA to help spot potentially deadly tumors and growths. Netflix’s ...